To the Editor: Maxwell and O'Leary's article1 and Wiltshire and Cameron's letter2 provide insights into the current issues facing newborn bloodspot screening (NBS) in Australia. It is clear that we have world-class NBS programs, but there is a lack of national policy guidance agreed on by governments. It has been argued that this has affected the programs' capacity to respond to the changing environment in which they operate.1,3,4 There is a need for clear national policies to support the programs' continued success and growth, and a way to assess the benefits and harms of screening additional conditions through NBS.5 Since the aforementioned articles were published, there has been substantial progress towards achieving these goals.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Maxwell SJ, O'Leary P. Newborn bloodspot screening: setting the Australian national policy agenda. Med J Aust 2014; 200: 142-143. <MJA full text>
- 2. Wiltshire E, Cameron F. Newborn bloodspot screening: setting the Australian national policy agenda [letter]. Med J Aust 2014; 201: 91-94. <MJA full text>
- 3. Warne GL, Armstrong KL, Faunce TA, et al. The case for newborn screening for congenital adrenal hyperplasia in Australia. Med J Aust 2010; 192: 107. <MJA full text>
- 4. Carpenter K. Newborn screening – 50 years on. Human Genetics Society of Australasia News [internet] 2013; 11 May. http://www.hgsa.org.au/news/newborn-screening-50-years-on (accessed Aug 2014).
- 5. Australian Health Ministers' Advisory Council, Screening Subcommittee. Population based screening framework. Canberra: Commonwealth of Australia, 2008. http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/pop-based-screening-fwork/$File/screening-framework.pdf (accessed Sep 2014).
No relevant disclosures.